Eli Lilly and Company (LLY) Fundamental Analysis
Eli Lilly and Company is in a high-growth phase, expanding revenue 56% year-over-year as it scales. It is solidly profitable, with a latest net margin of 37%. Cash generation is healthy, funding the business from its own operations. On the latest filing the majority of indicators are constructive.
Beat Index assesses Eli Lilly and Company across sixteen analysis tabs, spanning revenue and income, margins, cash flow, returns, liquidity and leverage, working capital, intrinsic value, commitments, insider activity, risk, and its latest 10-Q reads strongest on revenue growth, profit margins and cash generation while flagging balance-sheet strength for closer review. Every figure is taken as-reported from SEC EDGAR filings, with no vendor adjustments.
At a glance
- PositiveGrowth: Revenue up 56% YoY
- WatchBalance Sheet: Debt/equity 1.4x
- ConcernNo red flags in the latest quarter.
Trend matrix, last 4 quarters
| Dimension | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Growth | Revenue up 56% YoY | Revenue up 43% YoY | Revenue up 54% YoY | Revenue up 38% YoY |
| Profitability | Net margin 37% | Net margin 34% | Net margin 32% | Net margin 36% |
| Cash Generation | FCF margin 15% | FCF margin 4% | FCF margin 38% | FCF margin 9% |
| Balance Sheet | Debt/equity 1.4x | Debt/equity 1.6x | Debt/equity 1.8x | Debt/equity 2.2x |
Quarterly financials
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Revenue | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B |
| Cash & equivalents | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B |
| Net income | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B |
| Operating cash flow | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B |
| Free cash flow | $3.01B | $677.9M | $6.75B | $1.39B | $156.1M |
Figures in USD, as reported to the SEC. Longer history is available in the full analysis.
What's inside the full dashboard
Sixteen analysis tabs, all sourced from SEC filings, no estimates.
- Cash Flow: Free cash flow generation and operating cash flow trends.
- Intrinsic Value: Discounted cash flow (DCF) valuation and enterprise multiples.
- Liquidity & Leverage: Balance-sheet strength: assets, liabilities, debt and liquidity ratios.
- Margins: Gross, operating, and net profit margin analysis.
- Returns: Return on equity, return on assets, and return on invested capital.
- Revenue & Income: Revenue growth, composition, and year-over-year income trends.
- Working Capital: Working-capital efficiency, cash conversion and asset-turnover metrics.
- Risk: Debt levels, liquidity ratios, and financial risk indicators.
- Insider: Insider stock transactions and executive activity.
- Commitments: Operating leases, purchase commitments, and future obligations.
To see more, create a free account.
Create free accountUnlock the full Eli Lilly and Company dashboard
Live valuation, management commentary, and peer comparison, all sourced directly from SEC filings. Free to access.